Latest Shareholder Capital Raising News

New Murchison Gold Limited has had its trading suspension lifted following key approvals for its Crown Prince gold project and a related capital raising announcement.

Hawsons Iron Limited is raising up to $1 million through a discounted Share Purchase Plan to fund critical project development while continuing strategic investor discussions.

Alma Metals has announced a pro-rata non-renounceable rights offer to raise approximately $1.06 million, aiming to fund critical drilling and a scoping study at its Briggs Copper Project in Queensland.

EBR Systems has raised A$55.9 million through a fully underwritten placement to fund the commercial rollout of its FDA-approved wireless cardiac pacing system, with plans for a limited market release in H2 2025 and expanded distribution in 2026.

FFI Holdings has announced a $11 million non-renounceable entitlement offer priced at $3.50 per share, representing a notable discount to recent trading levels. The capital raise aims to fund property development and reduce debt, with directors backing the move by fully participating.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Terrain Minerals Ltd has announced a pro-rata entitlement offer to raise up to $1.82 million, supported by partial underwriting from directors Justin Virgin and Jason MacDonald. The capital raise aims to fund key exploration activities at the Smokebush Project and other initiatives.

ReNu Energy has completed the sale of its hydrogen division and is set to acquire Janus Electric, a pioneer in electric truck battery swapping, backed by a substantial capital raise to scale operations.

Infini Resources has successfully raised AUD$3.4 million through a flow-through share placement at a significant premium, positioning the company to aggressively advance exploration at its Portland Creek Uranium Project in Newfoundland.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.